Desyrel is an anti-depressant drug owned by Pragma. It contains the active ingredient trazodone hydrochloride and was first authorized for market use on the 25th of March, 1985.
The generic version of Desyrel is expected to become available after the 13th of March, 2029. This is due to the expiration of its last patent, US8133893, which holds until that date.
Desyrel, containing trazodone hydrochloride, is predominantly utilized for the treatment of depression. It works by modifying the balance of chemicals in the brain that contribute to mood disorders. It's also occasionally prescribed for insomnia and anxiety issues.
Desyrel currently holds a single patent, US8133893, titled 'Trazodone and trazodone hydrochloride in purified form'. This patent expires on the 13th of March, 2029, after which Desyrel generic alternatives can be released. Below are the details of the patent: